Pyrotinib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name: Pyrotinib
DrugBank Accession Number: DB14993
Background: Pyrotinib is under investigation in clinical trial NCT03756064 (Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer).
Type: Small Molecule
Groups: Investigational
Structure: 3D
MOL SDF 3D-SDF PDB SMILES InChI

Similar Structures
Structure for Pyrotinib (DB14993)
Synonyms: Not Available

Indication: Not Available
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings: Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics: Not Available
Mechanism of action: Not Available
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Not Available
Half-life: Not Available
Clearance: Not Available
Adverse Effects: Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity: Not Available
Pathways: Not Available
Pharmacogenomic Effects/ADRs: Not Available

Drug Interactions: This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions: Not Available

UNII: CJN36EQM0H
CAS number: 1269662-73-8
InChI Key: SADXACCFNXBCFY-IYNHSRRRSA-N
InChI: InChI=1S/C32H31ClN6O3/c1-3-41-30-17-27-25(16-28(30)38-31(40)12-10-24-8-6-14-39(24)2)32(21(18-34)19-36-27)37-22-9-11-29(26(33)15-22)42-20-23-7-4-5-13-35-23/h4-5,7,9-13,15-17,19,24H,3,6,8,14,20H2,1-2H3,(H,36,37)(H,38,40)/b12-10+/t24-/m1/s1
IUPAC Name: (2E)-N-[4-({3-chloro-4-[(pyridin-2-yl)methoxy]phenyl}amino)-3-cyano-7-ethoxyquinolin-6-yl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide
SMILES: CCOC1=C(NC(=O)\C=C\[C@H]2CCCN2C)C=C2C(=C1)N=CC(C#N)=C2NC1=CC=C(OCC2=NC=CC=C2)C(Cl)=C1

General References

Not Available

External Links

Clinical Trials

Phase	Status	Purpose	Conditions	Count
3	Active Not Recruiting	Treatment	Breast Cancer	1
3	Active Not Recruiting	Treatment	HER2 Exon 20 Mutation / Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)	1
3	Active Not Recruiting	Treatment	HER2/Neu-positive Breast Cancer	1
3	Active Not Recruiting	Treatment	Metastatic Breast Cancer	1
3	Active Not Recruiting	Treatment	Metastatic Breast Cancer With HER2 Positive	1
3	Not Yet Recruiting	Treatment	Breast Cancer	3
3	Not Yet Recruiting	Treatment	HER2 Low Breast Carcinoma / Hormone Receptor Positive Breast Carcinoma / Hormone-receptor-positive Breast Cancer / Invasive Breast Cancer / Stage I Breast Cancer	1
3	Recruiting	Treatment	Breast Cancer	1
3	Recruiting	Treatment	HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane	1
3	Recruiting	Treatment	HER2/Neu-positive Breast Cancer	1

State

Not Available

Experimental Properties

Not Available

Predicted Properties

Predicted ADMET Features

Not Available

Drug created at May 20, 2019 14:40 / Updated at June 12, 2020 16:53